Delta-Fly Pharma, Inc.
JPX: 4598.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kiyoshi Eshima
- Employees
- 13
- Headquarters
- Tokushima, Japan
- IPO year
- 2018
- Market cap
- ¥2.5B
- Website
- https://www.delta-flypharma.co.jp
Loading 4598…
Loading profile data…Frequently asked questions about 4598
What does Delta-Fly Pharma, Inc. (4598.T) do?
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the...
Where does 4598.T trade?
Delta-Fly Pharma, Inc. (4598.T) trades on the Tokyo Stock Exchange.
What sector is 4598.T in?
Delta-Fly Pharma, Inc. (4598.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Delta-Fly Pharma, Inc.?
Kiyoshi Eshima is the chief executive officer of Delta-Fly Pharma, Inc. (4598.T).
Where is Delta-Fly Pharma, Inc. headquartered?
Delta-Fly Pharma, Inc. is headquartered in Japan.
Does 4598.T pay a dividend?
Delta-Fly Pharma, Inc. (4598.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4598.T go public?
Delta-Fly Pharma, Inc. (4598.T) completed its initial public offering in 2018.